| ¿µ¹® | blood-brain barrier(BBB) | ÇÑ±Û | Ç÷³úÀ庮 |
|---|---|---|---|
| ¼³¸í | ³ú¿Í ô¼ö¿¡´Â Ç÷·ù·ÎºÎÅÍ ¾î¶² ¹°ÁúÀÌ À¯ÀԵǴ °ÍÀ» ¸·´Â À庮ÀÌ´Ù. À̰ÍÀº ³ú¿Í ô¼ö¿¡ Á¸ÀçÇÏ´Â ¸ð¼¼Ç÷°üÀÇ Åõ°ú¼ºÀÌ ºñ±³Àû ´Ù¸¥ ¸ð¼¼Ç÷°üÀÇ Åõ°ú¼ºº¸´Ù ¶³¾îÁö±â ¶§¹®ÀÌ´Ù. |
||
| ¿µ¹® | blood sugar | ÇÑ±Û | Ç÷´ç |
|---|---|---|---|
| ¼³¸í | Ç÷¾× ¼Ó¿¡ Æ÷ÇԵǾî ÀÖ´Â Æ÷µµ´ç. ³ú¿Í ÀûÇ÷±¸ÀÇ ¿¡³ÊÁö¿øÀÌ µÇ°í, ±× ¾çÀº ¿îµ¿, ½Ä»ç µûÀ§¿¡ ÀÇÇÏ¿© ´Þ¶óÁø´Ù. °Ç°ÀÎÀÇ ¾ÆÄ§ °øº¹½Ã Ç÷Áß Æ÷µµ´ç ³óµµ´Â 60~100mg/dL ÀÌÁö¸¸ ±âŸÀÇ ´çÁú Áï °ú´ç, °¥¶ôÅ佺, 5ź´çÀº ¹Ì·®À̸ç ÀϹÝÀûÀ¸·Î Ç÷´çÀ̶ó Çϸé Ç÷Á߯÷µµ´çÀ» ÀǹÌÇÑ´Ù. Ç÷´çÀº »ýüÀÇ ¿¡³ÊÁö¿øÀ¸·Î¼ °¡Àå Áß¿äÇÑ ¹°ÁúÀÌ´Ù. ±× ³óµµ´Â Àå°üÀ¸·ÎºÎÅÍÀÇ Èí¼ö, °£¿¡ ÀÖ¾î¼ÀÇ ´ç½Å»ý°ú ±Û¸®ÄÚ°ÕÀÌ ÇÕ¼º-ºÐÇØ, ¸»ÃÊÁ¶Á÷ÀÇ ´çÀÌ¿ë ÄáÆÏÀ¸·ÎºÎÅÍÀÇ ¹è¼³ µî ¿©·¯ ÀÎÀÚ¿¡ ÀÇÇØ Á¿ìµÇ¸ç ±× Á¶Àý¿¡´Â ÀÚÀ²½Å°æ°ú °¢Á¾ È£¸£¸óÀÌ ¹ÐÁ¢ÇÏ°Ô °ü°èÇÑ´Ù. ƯÈ÷ Ç÷´çÀúÇÏÀÛ¿ë¿¡´Â Àν¶¸°ÀÌ, ±×¸®°í Ç÷´ç»ó½ÂÀÛ¿ë¿¡´Â ¿¡Çdz×ÇÁ¸°, ±Û·çÄ«°ï, ¼ºÀåÈ£¸£¸ó, ºÎ½Å°ÑÁúÈ£¸£¸ó, ºÎ½Å°ÑÁúÀÚ±ØÈ£¸£¸ó, °©»ó»ù È£¸£¸óÀÌ °ü°è°¡ ÀÖÀ¸¸ç ±×°ÍµéÀÇ ´ëÇ× ¹× ÇùÁ¶ÀÛ¿ë¿¡ ÀÇÇØ Ç÷´çÄ¡°¡ Á¶ÀýµÈ´Ù. |
||
| ¿µ¹® | blood pressure | ÇÑ±Û | Ç÷¾Ð |
|---|---|---|---|
| ¼³¸í | Ç÷¾ÐÀ̶õ Ç÷°ü¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»ÇÏ´Â °ÍÀ¸·Î ´ë°³ Ưº°ÇÑ ¼³¸íÀÌ ¾øÀ¸¸é µ¿¸ÆÀÇ ¾Ð·ÂÀ» ¸»ÇÑ´Ù. Ç÷¾Ð¿¡´Â ¼öÃà±âÇ÷¾Ð(systolic blood pressure)°ú À̿ϱâÇ÷¾Ð(diastolic blood pressure)ÀÌ ÀÖ´Ù. ¼öÃà±âÇ÷¾ÐÀ̶õ ½ÉÀåÀÌ ¼öÃàÇÒ °æ¿ì¿¡ µ¿¸Æ¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»Çϰí, À̿ϱâ Ç÷¾ÐÀ̶õ ½ÉÀåÀÌ ÀÌ¿ÏÇÒ °æ¿ì¿¡ µ¿¸Æ¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»ÇÑ´Ù. ´ç¿¬È÷ ¼öÃà±â Ç÷¾ÐÀÌ À̿ϱâ Ç÷¾Ðº¸´Ù ³ô´Ù. Ç÷¾ÐÀ» ¸»ÇÒ ¶§¿¡ ¿¹¸¦ µé¾î 120/80mmHgÀ̶ó°í Àû´Â °ÍÀÇ ¾ÕÀÇ °ÍÀº ¼öÃà±â Ç÷¾ÐÀ» ÀǹÌÇÏ°í µÚ¿¡ Àû´Â 80Àº À̿ϱâ Ç÷¾ÐÀ» ÀǹÌÇÑ´Ù. |
||
| ¿µ¹® | blood | ÇÑ±Û | Ç÷¾×, ÇÇ |
|---|---|---|---|
| ¼³¸í | ¼øÈ¯±â, Áï ½ÉÀå°ú Ç÷°ü ¾ÈÀ» ¼øÈ¯ÇÏ´Â À¯µ¿¼ºÀÇ Á¶Á÷À» ¸»ÇÑ´Ù. Ç÷¾×Àº Àüü üÁßÀÇ ¾à 8%¸¦ Â÷ÁöÇϸç, ºñÁßÀº 1,056~1,059, Á¡µµ´Â ¾à 4.5, pH´Â 7.4ÀÌ´Ù. Ç÷¾×Àº ¾×ü¼ººÐÀÎ Ç÷Àå°ú °Å±â¿¡ ¶°µ¹°í ÀÖ´Â ¼¼Æ÷¼ººÐÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. Ç÷ÀåÀº Àüü Ç÷¾×ÀÇ 55%¸¦ Â÷ÁöÇÏ¸ç ¼öºÐ, ´Ü¹éÁú, Ç÷´ç, Áö¹æÁú, ¹«±â¿°·ù, Áú¼ÒÈÇÕ¹°·Î ÀÌ·ç¾îÁø´Ù. ¼¼Æ÷¼ººÐÀº Àüü Ç÷¾×ÀÇ 45%¸¦ Â÷ÁöÇϸç ÀûÇ÷±¸, ¹éÇ÷±¸, Ç÷¼ÒÆÇÀ¸·Î ÀÌ·ç¾îÁ® ÀÖ´Ù. Ç÷¾×ÀÇ ÁÖ¿ä ±â´ÉÀº Àü½Å Á¶Á÷À¸·Î »ê¼Ò¿Í ¿µ¾çºÐ °°Àº ÇÊ¿äÇÑ ¹°ÁúÀ» ¿î¹ÝÇÏ¸ç ºÒÇÊ¿äÇÑ ¹°ÁúÀ» ¹è¼³±â°üÀ¸·Î ¿î¹ÝÇÏ´Â ÀÏÀÌ´Ù. ±× ¹Û¿¡ »ýü¿¡ ÇØ·Î¿î ¹°ÁúÀ̳ª ¼¼±ÕÀ» Á¦°ÅÇϰí, ³»ºÎȯ°æÀÇ Çâ»ó¼ºÀ» À¯ÁöÇϸç, ü¿ÂÀ¯Áö¿Í »ýü ¹æ¾î ±â´ÉÀ» ÇÑ´Ù. »ç¶÷ÀÇ Ç÷¾×Àº ¿©·¯ °¡Áö ¼¼Æ÷ Ç÷±¸¿Í ±× ¼¼Æ÷¸¦ Æ÷ÇÔÇÏ´Â ¸¼Àº ¾×üÀÎ Ç÷Àå·Î ±¸¼ºµÇ¾î ÀÖ´Ù. Ç÷±¸´Â ÀûÇ÷±¸, ¹éÇ÷±¸, Ç÷¼ÒÆÇÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. ÀûÇ÷±¸´Â ºÓÀº »öÀ» ¶ì´Â ¼¼Æ÷·Î »ê¼Ò¸¦ ¸öÀÇ Á¶Á÷À¸·Î ¿î¹ÝÇÏ´Â ¿ªÇÒÀ» ÇÑ´Ù. Ç÷¼ÒÆÇÀº Ç÷¾×ÀÀ°í¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â ¼¼Æ÷ÀÌ´Ù. ¹éÇ÷±¸´Â Àΰ£ÀÇ ¸é¿ª¿¡ °ü°èÇÏ´Â ¼¼Æ÷ÀÌ¸ç ±¸Ã¼ÀûÀ¸·Î ´ÙÀ½°ú °°Àº ¼¼Æ÷µéÀÌ ÀÖ´Ù. 1.°ú¸³±¸(granulocyte): °ú¸³±¸¶õ ¹éÇ÷±¸ÀÇ 60%¸¦ Â÷ÁöÇϸç, ¼¼Æ÷¼Ó¿¡ ƯÀÌÇÑ °ú¸³À» °¡Áö°í ÀÖ´Â ¼¼Æ÷À̸ç, ´ÙÀ½°ú °°Àº 3°¡ÁöÀÇ ¼¼Æ÷°¡ À̰÷¿¡ Æ÷ÇÔÀÌ µÈ´Ù. -È£¿°±â±¸(basophil): ¿°±â¼º¿°»ö¾à¿¡ Àß ¿°»öµÇ´Â °ú¸³À» °¡Áö°í ÀÖ´Ù. ºÒ±ÔÄ¢ÇÑ ¸ð¾çÀÇ ¼¼Æ÷·Î Ǫ¸¥ »öÀ» ¶ì´Â °ú¸³ÀÌ ³Ê¹« ¸¹ÀÌ ÀÖ¾î¼ ÇÙÀÌ Àß º¸ÀÌÁö ¾Ê´Â´Ù. -È£»ê±¸(eosinophil): »ê¼º¿°»ö¾à¿¡ Àß ¿°»öµÇ´Â °ú¸³À» °¡Áö°í ÀÖ°í, ´ë°³ ±â»ýÃæÀÇ °¨¿°À̳ª, ¾Ë·¯Áö¿¡¼ ¸¹ÀÌ Áõ°¡ÇÑ´Ù. ´ë°³ 2°³ÀÇ ÇÙÀ» °¡Áö°í ÀÖÀ¸¸ç ÇÙ»çÀÌ¿¡ °¡´Â ½Ç°°Àº °ÍÀ¸·Î À̾îÁ® ÀÖ´Ù. -È£Áß±¸(neutrophil): »ê¼º¿°»ö¾àÀ̳ª ¿°±â¼º¿°»ö¾à¿¡ ÀÇÇÏ¿© ¸ðµÎ Àß ¿°»öµÇ´Â °ú¸³À» °¡Áö´Â ¼¼Æ÷·Î ´ë°³ 3°³ÀÇ ÇÙÀ» °¡Áø´Ù. ±×¸®°í ÇÙ»çÀÌ¿¡ °¡´Â ½Ç°°Àº ±¸Á¶¹°ÀÌ ÀÖ¾î¼ ÇÙÀ» ¼·Î À̾îÁÖ°í ÀÖ´Ù. 2.´ÜÇÙ±¸(monocyte): ´Ù°¢Çü¸ð¾çÀ» °¡Áø ¼¼Æ÷·Î °ú¸³À» °¡Áö°í ÀÖÁö ¾Ê´Ù. ¿Ü°è·ÎºÎÅÍ µé¾î¿Â ¹°ÁúÀ» Àâ¾Æ¸Ô´Â ¿ªÇÒ°ú ±×°Í¿¡ ´ëÇÑ Á¤º¸¸¦ Á¦°øÇÏ´Â ¿ªÇÒÀ» ÇÏ¿© ¸é¿ª¿¡ °ü°èÇÑ´Ù. À̰ÍÀÌ Ç÷¾× Áß¿¡ Á¸ÀçÇÏÁö ¾Ê°í Á¶Á÷¿¡ °íÁ¤µÇ¾î ÀÖ´Â °æ¿ì¿¡ À̰ÍÀ» Å«Æ÷½Ä¼¼Æ÷¶ó°í ÇÑ´Ù. 3.¸²ÇÁ±¸(lymphocyte): ÀÛÀº ¿øÇüÀÇ ¼¼Æ÷·Î ¸é¿ª¿¡ ÁßÃßÀûÀÎ ¿ªÇÒÀ» ÇÑ´Ù. |
||
| NAD | neutrophil actin dysfunction; new antigenic determinant; nicotinamide adenine dinucleotide; nicotini... |
|---|---|
| BMC | blood mononuclear cell; bone marrow cell; bone mineral content |
| CBF | capillary blood flow; cerebral blood flow; ciliary beat frequency; coronary blood flow; cortical blo... |
| HBF | hand blood flow; hemispheric blood flow; hemoglobinuric bilious fever; hepatic blood flow; hypothala... |
| CCL | carcinoma cell line; certified cell line; Charcot-Leyden crystal; continuing care level; critical ca... |
elevation (°Å»ó, »ó½Â, À¶±â, °íÀ§
| abnormal placental size | <radiology> TOO BIG (greater than5cm in sections obtained at right angles to the long axis), maternal disease, diabetic mothers (= villous oedema), intrauterine infections, anaemic mothers (= normal histology), foetal disease, erythroblatosis foetalis (= villous oedema and hyperplasia), umbilical vein obstruction, foetal high output failure, large chorioangioma, sacrococcygeal teratoma, arteriovenous fistula too small, preeclampsia (associated with placental infarcts in 33-60%) (12 Dec 1998) |
|---|---|
| reflex, abnormal | Abnormal, involuntary response to a stimulus which includes hyperreflexia, hyporeflexia, and areflexia. (12 Dec 1998) |
| cellular immunodeficiency with abnormal immunoglobulin synthesis | An ill-defined group of sporadic disorders of unknown cause, occurring in both males and females and associated with recurrent bacterial, fungal, protozoal, and viral infections; there is thymic hypoplasia with depressed cellular (T-lymphocyte) immunity combined with defective humoral (B-lymphocyte) immunity, although immunoglobulin levels may be normal. Synonym: Nezelof syndrome, Nezelof type of thymic alymphoplasia. (05 Mar 2000) |
| haemoglobins, abnormal | Haemoglobins altered in their genetically determined molecular structure, resulting in a characteristic complex of vlinival and laboratory abnormalities. The specific features of the abnormal haemoglobins are related to variation of the composite globin polypeptide chains. (12 Dec 1998) |
| pupillary functions, abnormal | Conditions in which the pupil does not react normally to dilation and constriction. Signs of pupillary abnormalities originate from the pupil's shape, position, and response to stimulation. (12 Dec 1998) |
| fibrinogens, abnormal | Fibrinogens which have a functional defect as the result of one or more amino acid substitutions in the amino acid sequence of normal fibrinogen. Abnormalities of the fibrinogen molecule may impair any of the major steps involved in the conversion of fibrinogen into stabilised fibrin, such as cleavage of the fibrinopeptides by thrombin, polymerization and cross-linking of fibrin. The resulting dysfibrinogenaemias can be clinically silent or can be associated with bleeding, thrombosis or defective wound healing. (12 Dec 1998) |
| ACE level | <investigation> This is a blood test which measures the concentration of angiotensin-converting enzyme (ACE) in the bloodstream. Elevations in angiotensin-converting enzyme are seen sarcoidosis, histoplasmosis, alcoholic cirrhosis, asbestosis, berylliosis, diabetes, Hodgkin's disease, hyperthyroidism, amyloidosis, primary biliary cirrhosis, idiopathic pulmonary fibrosis, pulmonary embolism, scleroderma, silicosis, tuberculosis, Gaucher's disease and leprosy. The normal values are 18 to 67 U/ml over 20 years of age (people under 20 have higher levels). (15 Jan 1998) |
| acoustic reference level | The biological reference level for sound measurements. When the term decibel is used to indicate the noise level, a reference quantity is implied; this reference value is usually expressed as a sound pressure of 20 micronewtons per square meter. The reference level is referred to as 0 decibels, the baseline of the scale of noise level's; this baseline is considered the weakest sound that can be heard by a person with very good hearing in an extremely quiet location. Other equivalent reference level's still being used include 0.0002 microbar and 0.0002 dyne per square centimeter. (05 Mar 2000) |
| background level | The average amount of a substance present in the environment. Originally referring to naturally occurring phenomena. Used in toxic substance monitoring. (05 Dec 1998) |
| vasopressin level | This test measures the amount of ADH in the serum. It is used to detect disorders that may affect the level of ADH in the serum. Normal values are: 0 to 4.7 pg/ml. Elevated ADH levels can indicate a CNS infection, fluid imbalance, CNS tumour, SIADH or acute porphyria. Low levels can indicate: diabetes insipidus or damage to the pituitary gland. (27 Sep 1997) |
| maximum permissible exposure level | The highest level of exposure to a substance, usually noxious, in the environment or during diagnostic and therapeutic procedures, that a body can tolerate without injury. (12 Dec 1998) |
| mean sea level | <marine biology> A tidal datum: the arithmetic mean of hourly water elevations observed over a specific 19-year cycle. Points on land can be referenced to a mean sea level, in which case the datum assumes zero elevation. (09 Oct 1997) |
| gray level also gray value | <microscopy> The brightness of pixels in a digitised video image, commonly expressed in integers ranging from 0 (black) to 255 (white) for an 8-bit digital signal. (05 Aug 1998) |
| gray level histogram | <microscopy> In digital image processing, a histogram that depicts the number of pixels at each gray value. The histogram can be used to measure the areas that have given ranges of gray values or to adjust image contrast by histogram stretching or equalisation. See: Image histogram. (05 Aug 1998) |
| Clark's level | The level of invasion of primary malignant melanoma of the skin; limited to the epidermis, I; into the underlying papillary dermis, II; to the junction of the papillary and reticular dermis, III; into the reticular dermis, IV; into the subcutaneous fat, V. The prognosis is worse with each successive deeper level of invasion. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|